Match!
Nature Reviews Clinical Oncology
IF
34.11
Papers
3426
Papers 3430
1 page of 343 pages (3,430 results)
Newest
The identification of biomarkers and the development of genomics-based assays predictive of outcomes following radiotherapy, in an effort to help guide the treatment of patients with cancer, is an area of increasing research interest. Here, we discuss the validity of one such classifier, ARTIC, in the context of complementary genomic approaches designed to predict both tumour response and the susceptibility of nonmalignant tissues to toxicities resulting from radiotherapy.
Source
#1Benjamin Carlisle (McGill University)H-Index: 5
#2Tiger Zheng (McGill University)H-Index: 1
Last.Jonathan Kimmelman (McGill University)H-Index: 26
view all 3 authors...
New molecular insights occasionally lead to the rapid development of therapeutic agents that improve the outcomes of patients with cancer; however, these breakthroughs can be followed by extensive, empirically driven and often unsuccessful efforts at extending the drug to other indications or combinations. Herein, we describe the clinical development of imatinib, a paradigm of rapid molecularly driven drug development, and advocate for a balanced portrayal of the potential of molecularly targete...
Source
Source
Source
Source
Source
Source
Source
#1Oliver Kepp (University of Paris)H-Index: 27
#2Aurélien MarabelleH-Index: 24
Last.Guido KroemerH-Index: 197
view all 4 authors...
Local administration of oncolytic viruses to tumours can promote anticancer immune responses that lead to the abscopal regression of distant metastases, especially in patients receiving systemic immune-checkpoint inhibitors. Growing preclinical evidence indicates that non-virally induced oncolysis, defined as chemical or physical treatment administered locally to destroy malignant lesions, can promote a similar effect owing to the release of danger-associated molecular patterns that lead to the ...
1 CitationsSource
As more patients with oncogene-driven non-small-cell lung cancer are treated with targeted therapies, they are joining forces online to form groups that provide support, education and advocacy focused on specific oncogenes. Herein, we discuss how the involvement of these groups in patient-partnered research can benefit both patients and lung cancer research.
Source
12345678910
Top fields of study
Cancer
Pathology
Oncology
Immunology
Medicine